CD4/CD8 ratio during human immunodeficiency virus treatment: time for routine monitoring?
R Ron, E Moreno, J Martínez-Sanz… - Clinical Infectious …, 2023 - academic.oup.com
In the last decade, studies in persons with HIV (PWH) on antiretroviral therapy (ART) have
shed light on the significance of persistently high CD8 counts and low CD4/CD8 ratios. A …
shed light on the significance of persistently high CD8 counts and low CD4/CD8 ratios. A …
Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: findings from a multinational cohort between 2010 and 2019
Background Broad direct-acting antiviral (DAA) access may reduce hepatitis C virus (HCV)
incidence through a" treatment as prevention"(TasP) effect. We assessed changes in …
incidence through a" treatment as prevention"(TasP) effect. We assessed changes in …
Expanding HIV clinical monitoring: the role of CD4, CD8, and CD4/CD8 ratio in predicting non-AIDS events
J Martínez-Sanz, J Díaz-Álvarez, MR Cancio-Suarez… - …, 2023 - thelancet.com
Background While a low CD4/CD8 ratio during HIV treatment correlates with
immunosenescence, its value in identifying patients at an increased risk for clinical events …
immunosenescence, its value in identifying patients at an increased risk for clinical events …
Determinants of long-term survival in late HIV presenters: the prospective PISCIS cohort study
R Martin-Iguacel, J Reyes-Urueña, A Bruguera… - …, 2022 - thelancet.com
Background Late HIV diagnosis (ie CD4≤ 350 cells/µL) is associated with poorer outcomes.
However, determinants of long-term mortality and factors influencing immune recovery …
However, determinants of long-term mortality and factors influencing immune recovery …
[Retracted] Research Progress on the Relationship between the NLRP3 Inflammasome and Immune Reconstitution in HIV‐Infected Patients Receiving Antiretroviral …
J Shi, Z Zhang, J Wu - Computational and Mathematical …, 2022 - Wiley Online Library
Human immunodeficiency virus (HIV) infection is characterized not only by severe
immunodeficiency but also by persistent inflammation and immune activation. These …
immunodeficiency but also by persistent inflammation and immune activation. These …
A novel prognostic score including the CD4/CD8 for AIDS-related lymphoma
J Chen, X Liu, S Qin, G Ruan, A Lu, J Zhang… - Frontiers in Cellular …, 2022 - frontiersin.org
Background A simple and clinically applicable prognostic scoring system for AIDS-related
lymphoma (ARL) in the era of combination antiretroviral therapy (cART) is needed to better …
lymphoma (ARL) in the era of combination antiretroviral therapy (cART) is needed to better …
Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events
S Serrano-Villar, K Wu, PW Hunt, JJ Lok, R Ron… - …, 2022 - thelancet.com
Background While increased CD8 counts and low CD4/CD8 ratio during treated HIV
correlate with immunosenescence, their additional predictive values to identify individuals …
correlate with immunosenescence, their additional predictive values to identify individuals …
[HTML][HTML] Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative …
B Chun, J Pucilowska, SC Chang, I Kim… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Chemoimmunotherapy is a standard treatment for triple-negative breast cancer
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
(TNBC), however, the impacts of different chemotherapies on T-cell populations, which …
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV
A González-Cordón, L Assoumou… - Journal of …, 2021 - academic.oup.com
Abstract Background Switching from boosted PIs to dolutegravir in people living with HIV
(PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 …
(PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 …
A retrospective clinical study of dolutegravir-versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China
M Zhong, M Li, M Qi, Y Su, N Yu, R Lv, Z Ye… - Frontiers in …, 2023 - frontiersin.org
Currently, there are limited data related to the efficacy and safety of ART regimens, as well
as factors influencing immune recovery in antiretroviral therapy (ART)-naïve patients with …
as factors influencing immune recovery in antiretroviral therapy (ART)-naïve patients with …